Navigation Links
Orexigen Therapeutics to Present at Upcoming Conferences
Date:2/9/2012

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences.  The details are as follows:

The 14th Annual BIO CEO & Investor Conference
Date:
February 13, 2012
Time:  1:30pm Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

Leerink Swann Global Healthcare Conference
Date:
February 15, 2012
Time:  8:00am Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Corporate Contacts: OrexigenOrexigen

MediaJay Hagan

Denise PowellChief Business Officer

WCG(858) 875-8673

(510)
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2012)... 21, 2012   Cord Blood America, Inc . ... ), the umbilical cord blood stem cell preservation ... of stem cells to families nationwide and internationally, today ... increased by 6.7%  to $1.55 million compared to $1.45 ... a gross profit of $1.12 million in the first ...
(Date:5/21/2012)... CITY, Panama, May 21, 2012 ... 16 May 2012 to discuss the potential use of ... a tool to combat Dengue Fever in Panama. ... Tropical Research Institute (STRI), The Gorgas Memorial Institute for ... together national and regional experts from these institutes as ...
(Date:5/18/2012)... HACKENSACK, N.J., May 18, 2012 Champions ... has received U.S. Clinical Laboratory Improvement Amendment (CLIA) ... Mental Hygiene Office of Health Care Quality required ... The Company,s President, Ronnie Morris, ... milestone for our Company. This approval validates the ...
(Date:5/17/2012)... 17, 2012 The " ... Study " analyzes and studies the U.S. market for ... anesthesia drugs in U.S., potential buyers, export & import system for ... Browse market data tables and in-depth TOC of ... 2015) -   U.S. Market Entry ...
Breaking Biology Technology:Cord Blood America Announces First Quarter Financial Results 2Cord Blood America Announces First Quarter Financial Results 3Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 3Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3
... of Madison is asking for bids on the construction of downtown ... would be able to charge user fees and would take on ... county and state for the right to operate. The project would ... said plans and costs are still not finalized. , ,Now, though, ...
... Madison, Wis. While the Madison chapter ... looking ahead for new social and technological developments, Scott Converse ... important if they want to see where the next big ... at the UW-Madison School of Business and founder of the ...
... anticipation of what may await them on Christmas morning. For me, ... companies vying for a place at February's DEMO@15 show. ... 70 or so companies that will debut at the show, there ... until the conference gems we can unwrap now. , ,One ...
Other Biology Technology:Madison asks for wireless bids; airport, downtown would be first 2Business-school IT director points to reasons for wireless trend 2An early Christmas gift 2
(Date:5/21/2012)... 2012 Researchers from Seattle Biomedical Research Institute (Seattle ... Edinburgh have uncovered new knowledge related to host-parasite interaction ... to bind to cells in the brain and cause ... disease. Three related papers will be published in the ... the National Academy of Sciences ), a premier scientific ...
(Date:5/21/2012)... 21, 2012  Chiltern International Limited (Chiltern), a ... has been recognized with a CRO Leadership Award ... and Regulatory. The awards are given by Life ... of Nice Insight. Glenn ... to be recognized as a CRO leader in ...
(Date:5/21/2012)... combination of cues in their hunting sequence - capture, handling ... and consume and which ones they are better off leaving ... listen to their prey, then they assess its size, and ... and her team from the Smithsonian Tropical Research Institute in ... The Science of Nature . , To survive, predators must ...
Breaking Biology News(10 mins):New discoveries about severe malaria 2Chiltern Wins CRO Leadership Award From Life Science Leader 2What sounds good doesn't always taste good 2Depression associated with sustained brain signals 12686 1Depression associated with sustained brain signals 12686 2Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast 70037 1Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast 70037 2Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast 70037 3Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast 70037 4Childhood Cancer Survivors At Higher Odds of Early Death 70034 1Childhood Cancer Survivors At Higher Odds of Early Death 70034 2
... In one of the first national studies on ... hospitals, researchers from the Indiana University School of ... Roudebush Veterans Administration Medical Center report that hospitals ... have lower rates of antibiotic resistance. , ...
... contracting a serious bacterial infection is that the victim ... destructive inflammation throughout the body, often leading to heart ... hospital intensive care units may be helpless to save ... study by Emory University and the Centers for Disease ...
... from HIV infection can lead to trouble when it ... appearing in the Oct. 1 issue of The Journal ... demonstrates that HIV-1 infected patients with suppressed immunity represent, ... group for malaria," says Jean-Pierre Van geertruyden, MD, MSc, ...
Other Biology News:Controlling antibiotics and antibiotic resistance in hospitals 2Researchers identify new weapon to fight deadly bacterial sepsis 2Researchers identify new weapon to fight deadly bacterial sepsis 3Malaria treatment efficacy compromised in certain HIV-positive patients 2
... Thermo Labsystems' Wellwash AC is ... microplate washer available, and is ... for wash, waste and rinse ... and automatic rinsing and priming ...
... Rabbit polyclonal to MLF1 Interacting Protein/PBIP1 ... all tested applications). ... to amino acids 73-83 of Human ... Entrez Gene ID: 359815 ...
... save space and organize gloves, safety ... They are the perfect benchtop storage ... labs, processing and manufacturing. Clear static-dissipative ... particles they attract. Many other sizes ...
... These handy dispensers save space ... wipers, hats, and other garb. ... storage bins for small parts ... manufacturing. Clear acrylic. Many other ...
Biology Products: